BioCryst Pharmaceuticals
BCRX
BCRX
112 hedge funds and large institutions have $370M invested in BioCryst Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 37 increasing their positions, 28 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more ownership
Funds ownership: →
more capital invested
Capital invested by funds: $ → $
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
32% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 28
9% more funds holding
Funds holding: 103 → 112 (+9)
Holders
112
Holding in Top 10
4
Calls
$25.2M
Puts
$8.02M
Top Buyers
| 1 | +$8.42M | |
| 2 | +$4.71M | |
| 3 | +$3.15M | |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.37M |
| 5 |
VMI
VHCP Management II
New York
|
+$2.22M |
Top Sellers
| 1 | -$7.37M | |
| 2 | -$4.11M | |
| 3 | -$2.56M | |
| 4 |
PC
Paulson & Co
New York
|
-$1.97M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.24M |